Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 1;9(1):43.
doi: 10.1186/1710-1492-9-43.

Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

Rosa Muñoz-Cano  1   2   3   4 , Antonio Valero  1   2   3   4 , Ignacio Izquierdo  5   6 , Jaume Sánchez-López  1   2   3   4 , Alejandro Doménech  5 , Joan Bartra  1   2   3   4 , Joaquim Mullol #  2   3   4   7 , Cesar Picado #  1   2   3   4
Affiliations

Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

Rosa Muñoz-Cano et al. Allergy Asthma Clin Immunol. .

Abstract

Background: Platelet-activating factor (PAF) is produced by most inflammatory cells and it is involved in inflammatory and allergic reactions. We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the upper airways.

Findings: Healthy volunteers (HV, N = 10) and seasonal allergic rhinitis (SAR, N = 10) asymptomatic patients were treated out of the pollen season with either rupatadine 20 mg, levocetirizine 10 mg, or placebo once a day during 5 days prior to the PAF nasal challenge. Total 4-nasal symptom score (T4SS) and nasal patency (Vol2-5, by acoustic rhinometry) were assessed from 0 to 240 minutes after a repeated PAF challenge. In SAR patients but not in HV, both rupatadine and levocetirizine showed a trend to decrease PAF-induced T4SS from 60 to 120 minutes. Rupatadine but not levocetirizine caused a significant reduction (p < 0.05) of T4SS area under the curve compared to placebo. Rupatadine and levocetirizine caused no significant changes on nasal patency compared to placebo.

Conclusions: These results suggest that both rupatadine and levocetirizine showed a tendency decrease toward nasal symptoms, but only rupatadine significally reduces the overall nasal symptoms (AUC) induced by PAF in SAR patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Squeme and design of study. PAF: platelel-activating factor; AcR: acoustic rhinometry; T4SS: total 4-symptoms score (evaluated by Likert and visual analogic scales) FEV1: Forced expiratory volume in 1 second.
Figure 2
Figure 2
Time-evolution on total nasal symptom score (T4SS) after repeated platelet-activating factor (PAF) nasal challengue, evalueted by Likert scale: (A) in healthy subjects, and (B) in seasonal allergic rhinitis (SAR) patients.
Figure 3
Figure 3
Area under of curve of nasal symptoms (AUC) of T4SS time-course adjusted by baseline values at 30 min.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Simons FE, Simons KJ. Histamine and H(1)-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;9(6):1139–1150. doi: 10.1016/j.jaci.2011.09.005. e4. - DOI - PubMed
    1. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, Garcia Rafanell J, Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF) J Pharmacol Exp Ther. 1997;9:114–121. - PubMed
    1. Leggieri E, Tedeschi A, Lorini M, Bianco A, Miadonna A. Study of the effects of paf-acheter on human nasal airways. Allergy. 1991;9:466–471. - PubMed
    1. Tedeschi A, Palumbo G, Milazzo N, Miadonna A. Nasal neutrophilia and esosinophilia induced by challenge with platelet activating factor. J Allergy Clin Immunol. 1994;9:526–533. - PubMed
    1. Klementsson H, Andersson M. Eosinophil chemotactic activity of topical PAF on the human nasal mucosa. Eur J Clin Pharmacol. 1992;9:295–299. - PubMed